Serves as a model for the development of other triazole antifungal agents.

Diflucan is a key agent whose utility is being challenged by shifting resistance patterns.

Diflucan is ineffective against Candida auris, a major multidrug-resistant pathogen.

Diflucan serves as first-line for many non-severe Candida albicans infections.

“Fluconazole-refractory” candidiasis is a specific clinical entity in advanced AIDS.

Teratogenicity concerns (Category D) limit its use in pregnancy, especially first trimester.

Serves as a benchmark for in vitro susceptibility testing of newer antifungals.

Emergence of resistance while on therapy necessitates repeat culture and susceptibility.

Activity against dermatophytes underpins its use in extensive tinea infections.

The development of rezafungin highlights the ongoing search for agents with fluconazole’s convenience but broader activity.